A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease.
Grail's blood test for detecting cancer early failed to meet its main goal in a giant study being conducted with England’s ...
By Kamal Choudhury and Mariam Sunny Feb 20 (Reuters) - Grail's shares plunged nearly 50% on Friday after the company said ...
Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.
The biotech company said its multi-cancer screening test Galleri did not lead to a “statistically significant reduction” in ...
Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...
Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic ...
Is the Galleri multi-cancer blood test worth it? A doctor explains real-world performance data and explains why no major ...
The results of a new study just came in.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results